Fisher & Paykel Healthcare (ASX:FPH) DeferredTaxAndRevenue: A$67 Mil (As of Mar. 2026)


ASX:FPH Fisher & Paykel Healthcare Corp Ltd ASX:FPH
90 GF Score
Price A$32.74
GF Value A$36.65
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Fisher & Paykel Healthcare DeferredTaxAndRevenue?

Fisher & Paykel Healthcare ASX:FPH +2.38% 90 DeferredTaxAndRevenue is A$67 Mil as of Mar. 2026. GuruFocus rates ASX:FPH with a GF Score™ of 90/100 and a GF Value™ of A$36.65 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Fisher & Paykel Healthcare's current deferred tax and revenue for the quarter that ended in Mar. 2026 was A$67 Mil.

Fisher & Paykel Healthcare DeferredTaxAndRevenue Related Terms

Fisher & Paykel Healthcare DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Fisher & Paykel Healthcare's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fisher & Paykel Healthcare DeferredTaxAndRevenue Chart

Fisher & Paykel Healthcare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.71 6.14 17.16 68.53 66.75

Fisher & Paykel Healthcare Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.16 23.62 68.53 32.91 66.75
ASX:FPH
90GF Score
Fisher & Paykel Healthcare Corp Ltd ASX:FPH
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of A$67 Mil mean?
Fisher & Paykel Healthcare (ASX:FPH) has a DeferredTaxAndRevenue of A$67 Mil as of Mar. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Fisher & Paykel Healthcare.
Is Fisher & Paykel Healthcare's DeferredTaxAndRevenue too high?
Fisher & Paykel Healthcare's current DeferredTaxAndRevenue is A$67 Mil. Overall, Fisher & Paykel Healthcare has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's DeferredTaxAndRevenue compare to ISRG and BDX?
Fisher & Paykel Healthcare's DeferredTaxAndRevenue of A$67 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Medical Devices & Instruments company?
A good DeferredTaxAndRevenue depends on the Medical Devices & Instruments industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Fisher & Paykel Healthcare. Fisher & Paykel Healthcare's current DeferredTaxAndRevenue is A$67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Modestly Undervalued. The stock's GF Value™ is A$36.65, compared to a current price of A$32.74 — trading 10.7% below its estimated fair value. The current DeferredTaxAndRevenue is A$67 Mil. Fisher & Paykel Healthcare's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current DeferredTaxAndRevenue is A$67 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?

Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued. The current stock price of A$32.74 is trading 10.7% below its estimated GF Value™ of A$36.65. GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.

Key valuation signals for ASX:FPH:

  • DeferredTaxAndRevenue: A$67 Mil
  • GF Value™: A$36.65 vs. price of A$32.74 (10.7% below fair value)
  • GF Score™: 90/100 with 2 warning signs

No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fisher & Paykel Healthcare Business Description

Other Exchanges FSPKF:USAFPH:New Zealand
Address 15 Maurice Paykel Place, East Tamaki, Auckland, NTL, NZL, 2013
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
90GF Score

Get the complete analysis for ASX:FPH

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$32.74
Price
A$36.65
GF Value